Tehran – HITCO has announced Katayoon Nojoomi as the new Chief Executive Officer (CEO) of Exon Salamat Tamin. This announcement marks a significant milestone in the company’s journey towards enhancing the sales and marketing strategies of healthcare products in Iran, aligning with ethical standards and regulatory requirements.
Katayoon Nojoomi, with an illustrious career spanning over two decades, brings to the table a profound expertise in pharmaceuticals and healthcare management. Before her groundbreaking appointment at Exon Salamat Tamin, Nojoomi played a pivotal role at Sanofi, where she dedicated three years as the Business Unit Head for Diabetes and Cardiovascular. Her tenure at Sanofi was marked by strategic leadership and innovative approaches to managing established products, notably in oncology and renal sectors, from March 2020 to April 2021, and as a member of the Sanofi Global Brand Team until March 2024.
Nojoomi’s career also shines light on her successful stint at Bayer Pharmaceuticals, where she served in capacities that demonstrated her adeptness in product management within the Gynecology and Andrology sectors. Her foundational experiences at Shahid Beheshti University as a supervisor of drug and medical equipment further solidify her credentials as a visionary leader in the healthcare domain.
Exon Salamat Tamin, established in 2020 as a key player under the HITCO umbrella, stands at the forefront of revolutionizing the sales and marketing landscape for healthcare products in Iran. With a focus on attracting top talent and leveraging industry-specific experience, the company prioritizes ethical practices, moral values, and adherence to health ministry regulations, setting a new standard in the healthcare sector.
